Muse Cell Therapy at Springs Rejuvenation: Inside Dr. Charles Pereyra's Research-Informed Approach
Medically reviewed by Dr. Charles Pereyra, MD — Medical Director, Springs Rejuvenation. Last reviewed October 7, 2026.
Written by the Springs Rejuvenation regenerative medicine team from direct clinical experience administering stem cell and exosome protocols at our Aventura, Miami center.
Springs Rejuvenation is one of the few clinics in the United States offering therapy built around Muse cells — the SSEA-3-positive, stress-enduring cell population first characterized by Dr. Mari Dezawa's laboratory in Japan. This article explains how Dr. Charles Pereyra and the Springs Rejuvenation team approach this emerging field, and the research that shapes each decision.
The Evidence Base Behind the Program
Rather than starting from marketing, the Springs program starts from the literature. Key reference points include the mechanistic work of Yamada and colleagues (2018), which described how Muse cells home to damaged tissue through the sphingosine-1-phosphate (S1P)–S1PR2 axis after intravenous delivery; the first-in-human CL2020 safety study in heart attack patients (Noda 2020); and the randomized stroke trial reported by Niizuma and colleagues in 2023, in which a higher proportion of Muse-supported patients reached favorable functional outcomes than placebo-supported patients. These are early studies with modest sample sizes — and that caveat is part of every patient conversation at Springs.
How the Research Shapes Care
Three principles follow directly from the trials. First, screening: published studies enrolled selected patients, so Springs evaluates candidacy through a physician-led consultation before discussing therapy. Second, characterized cells: the research used verified, SSEA-3-selected preparations, so provenance and quality documentation are non-negotiable. Third, honest framing: Muse cell therapy is investigational and not FDA approved, and the team says so directly — including to patients who ask whether they should instead travel overseas. One purpose of building this program domestically was precisely to give Americans a physician-supervised option without medical tourism.
What Patients Can Expect
Consultation, baseline labs, a personalized plan, supervised administration, and structured follow-up. The same educational-first approach extends to the clinic's broader regenerative programs for joints, hair, and wellness, each anchored to its own body of peer-reviewed research.
Why does Springs Rejuvenation emphasize research citations?
Because in an investigational field, the literature is the patient's best protection. Citing specific studies lets patients verify claims independently and understand both the promise and the limits of the data.
Who oversees muse cell therapy at Springs Rejuvenation?
Dr. Charles Pereyra leads the clinical program, with physician-led screening for every candidate and coordination with patients' existing physicians when appropriate.
Does Springs Rejuvenation guarantee results from muse cell therapy?
No, and no ethical clinic can. Individual responses vary, and the published trials, while encouraging, are early-stage. Expectations are set from the evidence, not from testimonials.
Is muse cell therapy at Springs Rejuvenation FDA approved?
No. Muse cell therapy is investigational in the United States. Springs Rejuvenation discloses this status to every patient as part of informed decision-making.
Medical Disclaimer: Stem cell and exosome therapy is not an FDA approved therapy and is considered to be in the experimental stages. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Springs Rejuvenation processes exosomes in an FDA approved lab. Individual results may vary. This content is reviewed for medical accuracy by Dr. Charles Pereyra, MD, Medical Director of Springs Rejuvenation, and is provided for educational purposes only. Always consult a qualified physician.